Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
| Revenue (TTM) | $11.15B |
| Gross Profit (TTM) | $7.31B |
| EBITDA | $2.85B |
| Operating Margin | 23.90% |
| Return on Equity | 10.10% |
| Return on Assets | 5.08% |
| Revenue/Share (TTM) | $2.50 |
| Book Value | $4.98 |
| Price-to-Book | 1.96 |
| Price-to-Sales (TTM) | 3.79 |
| EV/Revenue | 3.484 |
| EV/EBITDA | 13.83 |
| Quarterly Earnings Growth (YoY) | -4.50% |
| Quarterly Revenue Growth (YoY) | 2.20% |
| Shares Outstanding | $4.40B |
| Float | $4.43B |
| % Insiders | 0.01% |
| % Institutions | 13.54% |
Volatility is currently contracting
Investors interested in Consumer Products - Discretionary stocks are likely familiar with Lifetime Brands (LCUT) and Haleon PLC Sponsored ADR (HLN). But which of these two stocks presents investors with the better value opportunity right now?
Jefferies has raised its price target for Haleon (Haleon PLC (LSE:HLN, NYSE:HLN), the consumer health company behind Sensodyne and Advil, to 410p from 400p, maintaining its Buy rating. The broker highlighted a 70 basis point margin beat in the first half of the year, though it warned this revived concerns about whether Haleon was investing enough behind growth.
LONDON, Aug. 19, 2026 /PRNewswire/ -- Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the pricing terms, expiration and results of the offer to buy back any and all of the outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027 (the "Notes") of Haleon US Capital LLC's (the "Offeror"), the Company's wholly owned subsidiary (the "Tender Offer"). The Tender Offer has been made upon the terms and subject to the conditions set forth in the Offer to Purchase dated 11 August 2026 (the "Offer to Purchase").
LONDON, Aug. 11, 2026 /PRNewswire/ -- Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that its wholly owned subsidiary, Haleon US Capital LLC (the "Offeror") is offering to buy back any and all of its outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027. Bondholders will receive a price equal to the Total Consideration based on the Reference Yield and the Fixed Spread plus Accrued Interest (each as defined below) (the "Tender Offer").
Haleon plc (HLN) Q2 2026 Earnings Call Prepared Remarks Transcript
Investors with an interest in Consumer Products - Discretionary stocks have likely encountered both Acco Brands (ACCO) and Haleon PLC Sponsored ADR (HLN). But which of these two companies is the best option for those looking for undervalued stocks?
Haleon plc (HLN) Q2 2026 Earnings Call Transcript
Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 2.9% to 368.7p after the consumer healthcare group reported improving second-quarter sales but left its full-year guidance unchanged. Organic revenue increased 3.1% in the second quarter, split between 1.7% from pricing and 1.4% from volumes and product mix.
The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis, the ongoing US earnings season, and a series of key UK economic releases. Market participants digested the latest jobs, inflation, and retail sales data for July, all of which could influence the Bank of England's next policy decision.
Investors interested in stocks from the Consumer Products - Discretionary sector have probably already heard of Lifetime Brands (LCUT) and Haleon PLC Sponsored ADR (HLN). But which of these two stocks offers value investors a better bang for their buck right now?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HLN and any ticker you trade — then tracks every position and per-strategy win rate.
